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AbsTrACT
Objective troponin and B-type natriuretic peptide 
(BnP) concentrations are associated with cardiovascular 
risk in stable patients. Understanding their determinants 
and identifying modifiable clinical targets may improve 
outcomes. We aimed to establish clinical and cardiac 
determinants of these biomarkers.
Methods this was a prespecified substudy from the 
randomised scottish computed tomography of the heart 
trial, which enrolled patients 18–75 years with suspected 
stable angina between 2010 and 2014 (nct01149590). 
We included patients from six centres in whom high-
sensitivity troponin i and BnP were measured (singulex 
erenna). Patients with troponin >99th centile upper 
reference limit (10.2 ng/l) or BnP ≥400 ng/l were 
excluded to avoid inclusion of patients with myocardial 
injury or heart failure. Multivariable linear regression 
models were constructed with troponin and BnP as 
dependent variables.
results in total, 885 patients were included; 881 (99%) 
and 847 (96%) had troponin and BnP concentrations 
above the limit of detection, respectively. Participants 
had a slight male preponderance (n=513; 56.1%), and 
the median age was 59.0 (iQr 51.0–65.0) years. the 
median troponin and BnP concentrations were 1.4 
(iQr 0.90–2.1) ng/l and 29.1 (iQr 14.0–54.0) ng/l, 
respectively. age and atherosclerotic burden were 
independent predictors of both biomarkers. Male sex, 
left ventricular mass and systolic blood pressure were 
independent predictors of increased troponin. in contrast, 
female sex and left ventricular volume were independent 
predictors of increased BnP.
Conclusions troponin and BnP are associated 
with coronary atherosclerosis but have important sex 
differences and distinct and contrasting associations with 
ct-determined left ventricular mass and volume.
Clinical Trial registration nct01149590; Post-
results.
InTrOduCTIOn
The diagnostic and prognostic application of 
myocardial-specific plasma proteins is widely 
accepted in current practice. Two such cardio-
vascular biomarkers are high-sensitivity cardiac 
troponin and B-type natriuretic peptide (BNP). 
Although developed for use in specific populations, 
both are recognised to be important indicators of 
adverse prognosis among stable patients, even in 
the absence of established cardiac disease.1–4 These 
associations likely reflect the role of myocardial 
proteins as surrogate measures of underlying 
processes such as hypertension, atherosclerosis or 
left ventricular dysfunction.5 6 Indeed, there have 
been suggestions that measurement of high-sensi-
tivity troponin and BNP in certain asymptomatic 
populations may be of benefit.7 However, these tests 
are not specific for a single disease process. Under-
standing the drivers of biomarker concentrations in 
an individual patient is therefore crucial to facilitate 
interpretation of results and guide management.
Cardiac CT is a valuable investigation that is 
widely used for the diagnosis of coronary artery 
disease. However, it can also provide an assessment 
of left ventricular mass and volume, both of which 
are associated with elevated biomarker concentra-
tions.8 9 How these measures contribute to varia-
tions in biomarker concentrations in stable patients 
remains unclear.
In this biomarker substudy of the Scottish 
Computed Tomography of the Heart (SCOT-
HEART) trial, we aimed to establish the clinical 
and cardiac determinants of plasma high-sensi-
tivity cardiac troponin I and BNP concentrations 
in patients presenting with stable chest pain. We 
hypothesised that, in addition to recognised clin-
ical determinants, ventricular mass and volume as 
determined by cardiac CT would be associated with 
higher biomarker concentrations.
MeThOds
study design and population
This is a post-hoc analysis of the open-label, 
randomised SCOT-HEART trial. The trial design, 
primary analysis and 5-year outcomes have been 
published.10–12 Patients 18–75 years of age referred 
by a primary care physician to a cardiology clinic 
with stable chest pain were enrolled after obtaining 
written informed consent from 12 cardiology 
centres across Scotland. In total, 4146 patients were 
recruited from November 2010 to September 2014. 
Patients with severe chronic kidney disease (serum 
creatinine >200 μmol/L or estimated glomerular 
filtration rate <30 mL/min/1.73 m2) or acute coro-
nary syndrome within 3 months were excluded. All 
patients underwent routine clinical evaluation. A 
clinical diagnosis and management plan were docu-
mented prior to recruitment. Eligible patients were 
randomised 1:1 to receive routine care or routine 
care plus CT coronary angiography (CTCA).
For this substudy, we included patients who had 
been referred from six centres for their allocated 
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CTCA in Edinburgh (n=1317). As this study aimed to char-
acterise the determinants of baseline cardiac biomarkers in 
stable patients without acute myocardial injury or heart failure, 
patients with troponin concentrations >99th centile upper 
reference limit (10.2 ng/L) (n=29) or BNP ≥400 ng/L (n=11)13 
were excluded.
Computed tomography coronary angiography
The methods used to perform and to analyse coronary find-
ings from CTCA have been reported.12 Intraobserver and 
interobserver agreement were excellent (95% and 91%, respec-
tively).10 Atherosclerotic burden was quantified according to the 
CT-adapted Leaman score. This validated tool provides a score 
based on plaque location, composition (non-calcified, calcified 
or mixed) and degree of stenosis (<50% or ≥50%). The score 
has been validated in several cohorts; a cut-off of >5 provides 
additive prognostic value beyond stenosis alone.14
Left ventricular mass and volume
Cardiac CT assessments of myocardial mass and volume are vali-
dated and readily performed. Older protocols used retrospec-
tive electrocardiographic gating; however, prospective gating 
is now routine, with image acquisition performed in mid-dias-
tole. Although this limits the available phases, mid-diastolic left 
ventricular mass measurements correlate well with other phases 
and have prognostic value.15 Left ventricular mid-diastolic 
volume measurements also correlate with end-diastolic volumes 
and have prognostic importance,16 with established thresholds 
for normal ranges.17 18 Due to variation in volume measure-
ments across the cardiac cycle, we only included scans with gated 
images available between 70% and 90% of the R-R interval for 
this metric. In contrast, estimation of left ventricular mass is less 
affected by the cardiac cycle; we therefore included scans with 
images between 50% and 90% of the R-R interval.
Using automated software (Vitrea, Vital Images, Minnetonka, 
USA), left ventricular myocardial contours were detected during 
mid-diastole (75% phase or nearest acquired) in two planes and 
0.7 mm slices and manually adjusted to ensure accurate borders, 
allowing calculation of left ventricular volume and myocardial 
volume (from which myocardial mass is derived). Corrections 
for mid-diastolic acquisition were then applied15 19 to provide 
mass and estimated left ventricular end-diastolic volume. Values 
were indexed to body surface area (Du Bois formula). Left 
ventricular hypertrophy was defined as indexed left ventricular 
mass >79.2 g/m2 for men and >63.8 g/m2 for women—CT-spe-
cific thresholds with prognostic value.15
biomarker measurement
Troponin was measured using the Erenna high-sensitivity cardiac 
troponin I assay (Singulex, Alameda, California). The limit of 
detection is 0.1 ng/L with a 99th centile upper reference limit 
of 10.2 ng/L and a limit of quantification (LOQ; coefficient of 
variation <10%) of 0.4 ng/L.20 21 The BNP assay (Singulex) had 
a limit of detection of 2.0 ng/L and LOQ (coefficient of vari-
ation <10%) of 3.4 ng/L. EDTA-treated plasma samples were 
stored at −80°C.
statistical analysis
Analyses were performed using biomarker concentrations 
as continuous variables following log2 transformation. For 
descriptive purposes baseline characteristics are reported as 
median (IQR) according to troponin and BNP quantiles. Body 
mass index, systolic blood pressure, diastolic blood pressure, 
CT-adapted Leaman score, indexed left ventricular mass, indexed 
left ventricular volume and creatinine were log-transformed as 
a linearising transformation. Missingness was low, apart from 
creatinine (n=220, 25%) and indexed left ventricular volume 
(n=195, 22%; due to available scan phases and image quality). 
To avoid introducing bias by using complete case analysis, 
missing values were estimated by multivariable imputation by 
chained equations. Subsequent analyses were conducted using 
a single imputed value for each missing value. In a sensitivity 
analysis, the pooled parameters for the final models were also 
determined (online supplementary appendix).22 Patients with 
troponin or BNP concentrations below the lower limit of detec-
tion (n=4 and n=38, respectively) were assigned a value of half 
the lower limit of detection. Univariable and multivariable linear 
regression modelling were performed to identify the associations 
between each biomarker and relevant clinical, biochemical and 
imaging-derived variables. Included variables were CT-adapted 
Leaman score, left ventricular mass and volume indexed to body 
surface area, age (per decade), male sex, hypertension, hyperlip-
idaemia, diabetes, family history of coronary heart disease, docu-
mented coronary heart disease, smoking history, systolic blood 
pressure, diastolic blood pressure, body mass index, and serum 
creatinine. Sequential multivariable models were built, beginning 
with CT-adapted Leaman score and indexed left ventricular mass 
and volume, followed by the addition of clinical history, clinical 
measurements and biochemistry (online supplementary tables 1 
and 2). Two-sided p values <0.05 were considered statistically 
significant. Analysis was performed using R V.3.5.0 (R Founda-
tion for Statistical Computing, Vienna, Austria).
resuLTs
Patient characteristics
In total, 943 patients underwent biomarker sampling, of whom 
29 (3%) had a troponin concentration >99th centile upper refer-
ence limit and 11 (1%) had a BNP >400 ng/L. After excluding 
these patients and patients with missing BNP data, 885 patients 
were included. The median troponin concentration was 1.4 
(0.9–2.1) ng/L. The median BNP concentration was 29.1 (14.0–
54.0) ng/L (figure 1). Patients with higher biomarker concentra-
tions were older, more likely to have a history of coronary heart 
disease, be receiving medical therapies for cardiovascular condi-
tions and have a typical history of angina (table 1). Troponin 
concentrations were higher in men than in women (1.6 (1.1–
2.1) vs 1.0 (0.7–1.6) ng/L) in contrast to BNP concentrations 
which were higher in women than in men (31.9 (17.7–58.1) vs 
26.5 (12.5–50.0) ng/L). There was a weak correlation between 
troponin and BNP concentrations (Pearson’s r=0.21, p<0.001).
Coronary artery disease
Coronary CT angiography demonstrated normal coronary 
arteries in 309 (35%) patients, while 401 (45%) patients had 
stenoses of at least 50% (table 1). The median calcium score was 
30 (0.00–269.0) Agatston units. The median CT-adapted Leaman 
score was 4.0 (0.00–10.9), and 406 (46%) patients had high-risk 
coronary artery disease (CT-adapted Leaman score >5). In 576 
patients with evidence of any coronary artery disease on CT, the 
median calcium score was 143.5 (31.0–530.5) Agatston units, 
while the median CT-adapted Leaman score was 8.3 (4.4–14.2).
Left ventricular mass and volume
The median indexed left ventricular mass was 78.1 (71.1–86.1) g/
m2 for men and 62.6 (56.7–69.9) g/m2 for women. Nearly half 
(n=404, 46%) of patients met sex-specific CT criteria for left 
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ventricular hypertrophy. The median indexed left ventricular 
volume was 64.6 (56.6–71.3) mL/m2 for men and 62.1 (56.5–
68.0) mL/m2 for women.
determinants of plasma cardiac biomarkers
Univariable and sequential multivariable linear regression 
were performed using the prespecified variables for troponin 
(table 2) and BNP (table 3). There was an association between 
troponin and BNP measurements on univariable linear regres-
sion for both men and women (figure 1). For the final multivari-
able models, all prespecified covariates for troponin (r2=0.30, 
p<0.001) and BNP (r2=0.19, p<0.001) were included. Increasing 
age and atherosclerotic burden as assessed by CT-adapted Leaman 
score were independent predictors for increased troponin and 
BNP concentrations. Male sex and indexed left ventricular mass 
were predictors of increased troponin, in addition to hyper-
tension, systolic blood pressure and body mass index, but not 
BNP. In contrast, female sex and indexed left ventricular volume 
were predictors of increased BNP but not troponin. Of note, 
creatinine was a univariable predictor of increased troponin, but 
the association no longer remained after adjustment for other 
variables. Conversely, creatinine was a multivariable predictor of 
lower BNP. The biomarker-specific nature of these associations 
was confirmed on multivariable analysis of variance testing of 
the full model where both biomarkers were included as depen-
dent variables (bivariate multivariable regression). Furthermore, 
after standardising continuous variables, indexed left ventricular 
mass and volume provided the largest relative contribution to 
the explained variance within the troponin and BNP multivari-
able models, respectively, apart from age, which demonstrated 
the highest coefficient for both models (figure 2). Finally, to 
assess the potential effect of data imputation, complete case 
analysis was performed (n=495). Pooled model parameters 
were also determined (online supplementary tables 3 and 4). The 
multivariable models were largely unchanged. The direction and 
magnitude for the associations between age, gender, structural 
CT parameters, creatinine and both biomarkers were similar, 
although with expected variance in SEs.
dIsCussIOn
In this analysis from the SCOT-HEART trial, we describe clinical 
determinants of plasma high-sensitivity cardiac troponin I and 
BNP concentrations in a cohort of patients with suspected stable 
angina. We demonstrate the ability of cardiac CT to identify 
and characterise three distinct determinants of these biomarker 
concentrations: atherosclerotic burden, left ventricular mass and 
left ventricular volume. This has particular clinical relevance as 
troponin and BNP are powerful predictors of cardiovascular 
risk. These quantifiable imaging measures offer potentially 
modifiable targets for intervention.
It is imperative that patient-specific mechanisms for biomarker 
concentrations are understood. Are they a marker of an active, 
modifiable disease process, or simply sentinels for generalised, 
systemic inflammation and elevated cardiovascular risk? Without 
this understanding, targeted interventions cannot be applied, 
thereby diminishing the clinical benefits of additional prog-
nostic information. The importance of a mechanistic approach 
is demonstrated by the success of canakinumab, which specifi-
cally targets inflammation as a driver of cardiovascular events.23 
Importantly, a number of therapies have already been demon-
strated to address the processes we identified as contributing to 
increased biomarker concentrations. This provides a strong basis 
for using cardiac imaging when investigating the cause of these 
increased biomarker concentrations.
Our findings suggest that cardiac CT can achieve some of the 
necessary characterisation of biomarker determinants in stable 
patients. Obstructive coronary artery disease correlates with 
troponin concentrations in patients with stable angina.24 Here, 
we applied the CT-adapted Leaman score and demonstrate 
that, in addition to other clinical characteristics, this association 
persists after adjustment for left ventricular mass and volume. 
Although atherosclerotic disease is a chronic inflammatory 
process, changes within the vasculature are distinct from struc-
tural processes; cardiac CT facilitates the interrogation of both 
these aspects. Left ventricular mass measured at end-diastole 
using other modalities has been shown to correlate with eleva-
tions in cardiac biomarkers.25 Our study confirms a comparable 
relationship between troponin and mid-diastolic assessment of 
left ventricular mass on gated CT. Additionally, BNP concentra-
tions are elevated in heart failure or conditions with increased 
wall stress leading to left ventricular hypertrophy.9 However, we 
have demonstrated that after adjustment, left ventricular volume 
remains an independent determinant of BNP in stable patients 
without evidence of heart failure, whereas mass does not. The 
ability to perform these measurements with prospective gating 
is highly relevant in current practice. Of note, although we were 
unable to compare mid-diastolic left ventricular mass or volume 
directly with echocardiography or cardiac MRI, excellent 
correlation with other cardiac phases has been demonstrated 
previously.15 17 18
Our study is consistent with prior reports demonstrating 
an association between plasma biomarker concentrations and 
several clinical factors. Advanced age and male gender are both 
associated with increased troponin concentrations.6 8 There has 
Figure 1 Distribution of cardiac biomarkers between men and 
women. Panels A and B demonstrate the distribution of high-sensitivity 
troponin I (hsTnI) and B-type natriuretic peptide (BNP), stratified by 
gender. Dashed lines represent median values for hsTnI (1.4 ng/L) and 
BNP (29.1 ng/L) for the whole cohort. Panel C represents univariable 
linear regression modelling that demonstrates the weak association 
between hsTnI and BNP for both women (r2=0.03, coefficient 0.13, 
p<0.001) and men (r2=0.09, coefficient 0.16, p<0.001).
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been considerable research into determining age-specific and 
sex-specific 99th centile thresholds for each assay. Although 
posited explanations include a higher atherosclerotic burden 
in the elderly and increased myocardial mass in men, we have 
shown that age and male gender remain predictors of higher 
troponin concentrations even after adjusting for these variables. 
Likewise, we also describe the association between female sex and 
increased BNP which persisted after adjustment for confounders 
such as age, atherosclerotic burden and left ventricular mass and 
volume—variables that are not reported in previous studies. This 
demonstrates the utility of cardiac CT in delineating how coro-
nary and structural parameters contribute to BNP elevation.3 
The precise mechanisms for these independent gender differ-
ences are unclear. Hormonal differences are likely to contribute. 
Oestrogen has an attenuating effect on atherosclerosis and left 
ventricular hypertrophy,26 while testosterone suppresses natri-
uretic peptide production, resulting in lower concentrations.27 
Although the mechanisms are uncertain, our findings support 
the application of sex-specific reference ranges, and further-
more point towards the need for age-specific cut-offs. Universal 
thresholds may misclassify patients, potentially leading to inap-
propriate therapies.
In contrast to prior reports that elevated troponin concen-
trations are more common in outpatients with chronic kidney 
disease,28 29 we found that a higher creatinine was not an inde-
pendent predictor of increased troponin. In contrast, creatinine 
was associated with a lower BNP concentration after multi-
variable adjustment. Although unexpected, it should be noted 
Table 1 Baseline characteristics for overall cohort and according to high-sensitivity cardiac troponin I and BNP quantiles (below/above median)
Overall
n=885
hs-cTnI bnP
Low (≤1.4 ng/L)
n=443
high (>1.4 ng/L)
n=442 P value
Low (≤29.1 ng/L)
n=443
high (>29.1 ng/L)
n=442 P value
Male 494 (55.8) 192 (43.3) 302 (68.3) <0.001 267 (60.3) 227 (51.4) 0.009
Age 59.0 (51.0–65.0) 55.0 (48.0–63.0) 62.0 (55.0–67.0) <0.001 55.0 (48.0–62.0) 62.0 (55.0–67.0) <0.001
Hypertension 325 (36.7) 119 (26.9) 206 (46.6) <0.001 149 (33.6) 176 (39.8) 0.07
Hyperlipidaemia 528 (59.7) 246 (55.5) 282 (63.8) 0.015 233 (52.6) 295 (66.7) <0.001
Diabetes 91 (10.3) 41 (9.3) 50 (11.3) 0.37 50 (11.3) 41 (9.3) 0.38
Known CAD 77 (8.7) 24 (5.4) 53 (12.0) 0.001 23 (5.2) 54 (12.2) <0.001
Family history of CAD 383 (43.3) 214 (48.3) 169 (38.2) 0.003 199 (44.9) 184 (41.6) 0.36
Smoking history
  Non-smoker 396 (44.7) 192 (43.3) 204 (46.2) 0.009 203 (45.8) 193 (43.7) 0.07
  Ex-smoker 313 (35.4) 145 (32.7) 168 (38.0) 142 (32.1) 171 (38.7)
  Current smoker 176 (19.9) 106 (23.9) 70 (15.8) 98 (22.1) 78 (17.6)
Atrial fibrillation 14 (1.6) 6 (1.4) 8 (1.8) 0.78 8 (1.8) 6 (1.4) 0.79
Cerebrovascular disease 38 (4.3) 18 (4.1) 20 (4.5) 0.87 16 (3.6) 22 (5.0) 0.40
PVD 17 (1.9) 8 (1.8) 9 (2.0) 1.00 7 (1.6) 10 (2.3) 0.63
Chest pain type
  Non-anginal 303 (34.2) 179 (40.4) 124 (28.1) <0.001 183 (41.3) 120 (27.1) <0.001
  Atypical angina 211 (23.8) 119 (26.9) 92 (20.8) 108 (24.4) 103 (23.3)
  Typical angina 371 (41.9) 145 (32.7) 226 (51.1) 152 (34.3) 219 (49.5)
Systolic blood pressure (mm Hg) 140.0 (128.0–154.0) 138.0 (124.0–151.0) 140.0 (130.0–156.8) <0.001 140.0 (128.0–152.0) 140.0 (128.0–155.0) 0.30
Diastolic blood pressure 
(mm Hg)
81.0 (76.0–90.0) 80.0 (75.0–90.0) 82.0 (76.0–90.0) 0.04 82.0 (77.0–90.0) 80.0 (75.0–90.0) 0.12
BMI (kg/m2) 28.7 (25.9–32.6) 28.6 (25.5–32.3) 29.0 (26.2–32.9) 0.13 29.1 (26.3–33.3) 28.2 (25.5–32.2) 0.02
Antiplatelet 448 (50.6) 189 (42.7) 259 (58.6) <0.001 183 (41.3) 265 (60.0) <0.001
Statin 393 (44.4) 171 (38.6) 222 (50.2) 0.001 158 (35.7) 235 (53.2) <0.001
ACE inhibitor 123 (13.9) 40 (9.0) 83 (18.8) <0.001 48 (10.8) 75 (17.0) 0.01
Beta-blocker 202 (22.8) 84 (19.0) 118 (26.7) 0.008 72 (16.3) 130 (29.4) <0.001
ASSIGN score 16.0 (10.0–23.0) 13.0 (8.0–21.0) 18.0 (13.0–26.0) <0.001 14.0 (9.0–22.0) 17.0 (12.0–25.0) <0.001
Creatinine (µmol/L) 91.1
(76.7–109.5)
88.6
(74.4–106.3)
93.5
(79.6–111.7)
<0.001 91.4
(77.4–111.4)
90.6
(76.5–108.2)
0.3
hs-cTnI (ng/L) 1.3 (0.9–2.1) 0.9 (0.7–1.1) 2.1 (1.6–3.2) <0.001 1.2 (0.8–1.8) 1.5 (1.0–2.4) <0.001
BNP (ng/L) 29.1 (14.2–54.0) 24.9 (11.2–44.1) 34.9 (19.2–67.1) <0.001 14.2 (7.8–21.7) 54.1 (39.6–83.8) <0.001
CAD
  Normal 309 (34.9) 204 (46.0) 105 (23.8) <0.001 178 (40.2) 131 (29.6) <0.001
  Mild (<50%) 175 (19.8) 88 (19.9) 87 (19.7) 94 (21.2) 81 (18.3)
  Moderate (50%–70%) 159 (18.0) 77 (17.4) 82 (18.6) 76 (17.2) 83 (18.8)
  Obstructive (>70%) 242 (27.3) 74 (16.7) 168 (38.0) 95 (21.4) 147 (33.3)
CT-adapted Leaman score 4.0 (0.0–10.9) 1.5 (0.0–6.9) 7.0 (0.9–14.4) <0.001 3.1 (0.0–8.7) 5.5 (0.0–12.2) <0.001
Calcium score (Agatston units) 30.0 (0.0–269.0) 3.0 (0.0–95.0) 103.5 (1.2–546.5) <0.001 11.0 (0.0–136.5) 63.5 (0.0–430.2) <0.001
Indexed left ventricular volume 
(mL/m2)
63.2 (56.6–69.5) 63.2 (57.2–69.6) 62.5 (55.8–69.3) 0.30 62.6 (56.2–69.7) 63.2 (56.9–69.4) 0.72
Indexed left ventricular mass 
(g/m2)
71.7 (62.6–81.5) 67.6 (59.6–76.8) 75.7 (67.6–84.4) <0.001 72.6 (63.4–81.7) 70.8 (61.6–81.2) 0.17
Left ventricular hypertrophy 404 (45.6) 174 (39.3) 230 (52.0) <0.001 203 (45.8) 201 (45.5) 0.97
Continuous variables are presented as median (IQR).
Categorical variables are presented as n (%).
BMI, body mass index; BNP, B-type natriuretic peptide; CAD, coronary artery disease; CTCA, CT coronary angiography; hs-cTnI, high-sensitivity cardiac troponin I; PVD, peripheral vascular disease.
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BNP has been reported as less sensitive to changes in renal func-
tion than N-terminal proBNP, while increased concentrations 
are typically seen in patients with advanced renal impairment 
that would have been ineligible for the SCOT-HEART trial.29 
Indeed, there were relatively few patients in this cohort with 
renal impairment. Furthermore, as discussed below, there is 
a degree of variability in BNP assays that is driven by several 
factors. Small changes in serum creatinine may also be caused 
by factors which we did not control for, such as certain medica-
tions. Nevertheless, our findings suggest that in the context of 
preserved or mildly impaired renal function, changes in plasma 
troponin I and BNP concentrations are due to comorbid condi-
tions rather than renal dysfunction.
Our study has several strengths. First, we applied a troponin 
assay with exceptional analytical characteristics, enabling us to 
detect circulating troponin in 99.6% of the study population 
and to determine troponin concentrations accurately in 96.8%. 
Second, we made use of state-of-the-art CT imaging using a 
320-slice scanner to quantify coronary atherosclerotic burden 
and left ventricular mass and volume according to previously 
validated techniques. Third, as this study was nested within a 
trial randomising allocation to CT imaging, we have minimised 
case ascertainment bias that may arise when imaging decisions 
are dependent on clinical suspicion of coronary disease. Finally, 
we achieved detailed and accurate phenotypic characterisation 
of participants.
Table 2 Univariable and multivariable associations for high-sensitivity cardiac troponin I concentration
univariable regression analysis Multivariable regression analysis*: r2=0.30
Coefficient 95% CI P value Coefficient 95% CI P value
Age (per 10 years) 0.37 0.30 to 0.44 <0.001 0.33 0.25 to 0.41 <0.001
Male 0.60 0.47 to 0.73 <0.001 0.25 0.10 to 0.40 0.002
Hypertension 0.49 0.35 to 0.63 <0.001 0.17 0.04 to 0.30 0.011
Hyperlipidaemia 0.29 0.15 to 0.43 <0.001
Diabetes 0.19 −0.04 to 0.41 0.11
Documented CAD 0.40 0.16 to 0.64 0.001
Family history of CAD −0.23 −0.37 to −0.10 0.001
Ex-smoker 0.03 −0.12 to 0.19 0.68
Current smoker −0.15 −0.34 to 0.03 0.10
BMI (log2) 0.15 −0.11 to 0.41 0.27 0.24 0.00 to 0.47 0.048
Systolic blood pressure (log2) 1.16 0.83 to 1.49 <0.001 0.52 0.17 to 0.87 0.004
Diastolic blood pressure (log2) 0.49 0.16 to 0.82 0.004
CT-adapted Leaman score (log2) 0.19 0.16 to 0.23 <0.001 0.06 0.02 to 0.10 0.007
Indexed left ventricular mass (log2) 1.37 1.13 to 1.61 <0.001 0.92 0.64 to 1.20 <0.001
Indexed left ventricular volume (log2) 0.01 −0.27 to 0.28 0.96
Creatinine (log2) 0.41 0.22 to 0.61 <0.001
*All covariates were included in the final multivariable linear regression model; only those with p<0.05 are presented. Full modelling is presented in online supplementary table 
1.
BMI, body mass index; CAD, coronary artery disease.
Table 3 Univariable and multivariable associations for B-type natriuretic peptide
univariable regression analysis Multivariable regression analysis*: r2=0.18
Coefficient 95% CI P value Coefficient 95% CI P value
Age (per 10 years) 0.6 0.49 to 0.71 <0.001 0.54 0.41 to 0.67 <0.001
Male −0.32 −0.54 to −0.10 0.005 −0.33 −0.60 to −0.06 0.016
Hypertension 0.31 0.09 to 0.54 0.007
Hyperlipidaemia 0.55 0.33 to 0.77 <0.001
Diabetes −0.22 −0.58 to 0.14 0.23
Documented CAD 0.74 0.35 to 1.12 <0.001 0.46 0.09 to 0.84 0.016
Family history of CAD −0.07 −0.30 to 0.15 0.52
Ex-smoker 0.22 −0.03 to 0.47 0.082
Current smoker −0.24 −0.54 to 0.05 0.11
BMI (log2) −0.45 −0.87 to −0.03 0.035
Systolic blood pressure (log2) 0.61 0.06 to 1.16 0.028
Diastolic blood pressure (log2) −0.36 −0.90 to 0.18 0.19
CT-adapted Leaman score (log2) 0.2 0.13 to 0.26 <0.001 0.12 0.05 to 0.19 0.001
Indexed left ventricular mass (log2) −0.3 −0.71 to 0.11 0.15
Indexed left ventricular volume (log2) 0.3 −0.15 to 0.74 0.19 1.24 0.79 to 1.69 <0.001
Creatinine (log2) −0.39 −0.71 to −0.06 0.019 −0.42 −0.74 to −0.11 0.008
*All covariates were included in the final multivariable linear regression model; only those with p<0.05 are presented. Full modelling is presented in online supplementary table 
2.
BMI, body mass index; CAD, coronary artery disease.
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There are several limitations. First, key exclusion criteria for 
the study included age >75 years or severe renal impairment 
(estimated glomerular filtration rate <30 mL/min/1.73 m2); the 
determinants of biomarker concentrations in these contexts 
therefore remain uncertain. Nevertheless, SCOT-HEART was 
pragmatic in design, enrolling a cohort broadly representa-
tive of real-world populations with suspected stable angina. 
Second, without serial plasma samples, we cannot be certain that 
biomarker values reflect true baseline concentrations. However, 
participants were recruited in a stable outpatient setting and 
we excluded individuals with troponin concentrations above 
the 99th centile and BNP >400 ng/L,13 thereby minimising the 
possibility of including patients with acute myocardial injury or 
heart failure. Third, there is some biological, genetic and analyt-
ical variability in biomarker concentrations. Current BNP assays 
measure a mixture of peptides, including degradation products 
and proBNP, while degradation in frozen BNP samples over 
time is well described. These limitations are common to current 
assays, including N-terminal proBNP assays. Furthermore, the 
clinical characteristics associated with troponin and BNP that 
we describe are largely consistent with existing data, supporting 
the validity of our analysis, while BNP degradation appears to 
be more relevant at higher concentrations.30 Fourth, although 
the assessment of left ventricular mass and volume using cardiac 
CT is an accepted and accurate method, mid-diastolic assess-
ment is less widely studied. This may account for the relatively 
high prevalence of left ventricular hypertrophy as defined by 
previously published thresholds, although more than one-third 
of patients had a diagnosis of hypertension. Finally, despite the 
detailed characterisation of this cohort, substantial unexplained 
variance in troponin and BNP concentrations remains, high-
lighting the need for ongoing research to better understand the 
information that these assays offer.
COnCLusIOns
Detectable plasma high-sensitivity cardiac troponin I and BNP 
concentrations are present in almost all patients with suspected 
stable coronary artery disease. These biomarkers are associated 
with atherosclerotic burden, but measures of underlying left 
ventricular structure are associated with each biomarker differ-
entially. Cardiac biomarkers provide information regarding 
patient-specific modifiable targets for therapy, allowing person-
alisation of treatment that may further help reduce cardiovas-
cular risk.
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Figure 2 Multivariable logistic regression analysis for cardiac 
biomarkers. Multivariable logistic regression and relative contribution 
from selected covariates to biomarker concentrations. Log-transformed 
continuous covariates from the final multivariable models for high-
sensitivity troponin I (hsTnI) and B-type natriuretic peptide (BNP) were 
selected and scaled ((x – mean)/SD) in order to present each variable’s 
relative contribution to the final model. 95% CIs are provided for both 
troponin (y axis) and BNP (x axis).
Key messages
What is already known on this subject?
 ► Increased cardiac troponin and B-type natriuretic (BNP) 
concentrations are associated with greater risk of 
cardiovascular events in individuals with and without 
established cardiac disease.
 ► Plasma concentrations in stable outpatients may be 
attributable to pathophysiological processes including 
hypertension, coronary atherosclerosis and left ventricular 
dysfunction, but clinical determinants are not fully 
characterised.
What might this study add?
 ► We demonstrate the association between overall plaque 
burden as assessed by CT coronary angiography (CTCA) and 
troponin and BNP concentrations.
 ► Importantly, we describe sex differences and contrasting 
associations with left ventricular mass and volume.
 ► We also demonstrate the ability of prospectively gated 
CTCA performed primarily for coronary artery assessment to 
provide additional information regarding ventricular mass 
and volume.
how might this impact on clinical practice?
 ► Although plasma troponin and BNP have prognostic value in 
stable patients, an understanding of their determinants—and 
specifically, modifiable determinants—is necessary to add 
clinical utility.
 ► With this knowledge, these plasma biomarkers have the 
potential to act as simple surrogate markers of treatment 
efficacy for targeted disease-modifying therapies.
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